Dr. Alexander Olawaiye: Inside Platinum Resistant Ovarian Cancer - Actions & Insights

Connect Ovar Coffee: Dr. Alexander OlawaiyeThis episode features Dr. Alexander Olawaiye, discussing major advances in ovarian cancer treatment, including the ROSELLA clinical trial.  Key Highlights: 1. Ovarian Cancer Challenges: - No reliable early screening methods - Majority diagnosed at advanced stages (Stage III/IV) - Early detection remains a critical unmet need 2. ROSELLA Trial Breakthrough: - Focus on platinum-resistant ovarian cancer - Combines relacorilant (a glucocorticoid receptor antagonist) with nab-paclitaxel - Demonstrated improved progression-free survival and overall survival - No biomarker requirement, making it accessible to more patients 3. Mechanism of Action: - Relacorilant blocks cortisol signaling that promotes chemotherapy resistance - Enhances effectiveness of chemotherapy 4. Safety & Tolerability: - No new major toxicities identified - Side effects consistent with standard chemotherapy 5. Clinical Trial Importance: - Patients in trials often experience better outcomes - Participation helps advance future treatments 6. Health Equity & Access: - Disparities exist in access to care and clinical trials - Need to improve awareness, access, and inclusion 7. Future Outlook: - Rapid growth in new treatments over past decade - Emerging therapies include antibody-drug conjugates - Continued innovation offers hope for patients  Closing Message:Stay informed, consider clinical trials, and remain hopeful as new treatments continue to emerge.